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Abstract
Background—During the past decade, in the United States, an increasing number of hepatitis B 
outbreaks have been reported in assisted living facilities (ALFs) as a result of breaches in infection 
control practices. We evaluated the seroprotection rates conferred by hepatitis B vaccine among 
older adults during a response to an outbreak that occurred in multiple ALFs and assessed the 
influence of demographic and clinical factors on vaccine response.
Methods—Residents were screened for hepatitis B and C infection prior to vaccination and 
susceptible residents were vaccinated against hepatitis B with one dose of 20 μg Engerix-B™ 
(GSK) given at 0, 1, and 4 months. Blood samples were collected 80–90 days after the third 
vaccine dose to test for anti-HBs levels.
Results—Of the 48 residents who had post-vaccination blood specimens collected after the third 
vaccine dose, 16 (33.3%) achieved anti-HBs concentration ≥10 mIU/mL. Age was a significant 
determinant of seroprotection with rates decreasing from 88% among persons aged ≤60 years to 
12% among persons aged ≤90 years (p = 0.001). Geometric mean concentrations were higher 
among non-diabetic than diabetic residents, however, the difference was not statistically 
significant (5.1 vs. 3.8 mIU/mL, p = 0.7).
Conclusions—These findings highlight that hepatitis B vaccination is of limited effectiveness 
when administered to older adults. Improvements in infection control and vaccination at earlier 
ages might be necessary to prevent spread of infection in ALFs.
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1. Introduction
Hepatitis B virus (HBV) infection is a bloodborne and sexually transmitted infection that 
affects almost 730,000 persons in the United States with highest prevalence rates reported 
among persons aged 50 years or older compared to younger age groups [1]. The main 
consequences of HBV infection include cirrhosis, liver cancer, and death. Hepatitis B 
vaccination is the most effective measure to prevent HBV infection and its consequences. 
The Centers for Disease Control and Prevention (CDC) and the Advisory Committee for 
Immunization Practices (ACIP) recommend universal vaccination for all children and 
adolescents, as well as adults who are at high risk for HBV infection [2].
While the achievement of seroprotection (anti-HBs ≥ 10 mIU/mL) after receipt of hepatitis 
B vaccine has been established among persons aged less than 40 years, limited data are 
available regarding anti-HBs response among those aged 60 years or older. Outbreaks of 
HBV infection, with many acute infections resulting in death, are increasingly being 
recognized in long-term care (LTC) facilities as a result of improper cleaning and sharing of 
blood glucose monitoring devices [3–6]. Projections indicate that the number of persons in 
the United States 65 years of age or older is expected to double to more than 70 million by 
2030 with a concomitant increase in the number of residents in LTC facilities [7]. To 
prevent HBV infections among residents of LTC facilities, assiduous adherence to infection 
control guidelines is essential; however, adherence has proven challenging in such settings 
in the absence of federal oversight and variable state regulations regarding infection control 
practices [7].
The extent to which hepatitis B vaccination might be useful for susceptible persons living in 
LTC facilities is not clear, particularly in the acute context of prevention of HBV 
transmission during an outbreak. We evaluated the immunogenicity of monovalent hepatitis 
B vaccine administered to older adults during an outbreak that occurred in multiple assisted 
living facilities (ALFs) in one city and assessed the influence of demographic and clinical 
factors on vaccine response.
2. Materials and methods
2.1. Study population
In June 2010, an outbreak of acute hepatitis B was identified in four ALFs housing a total of 
289 older adults in the city of Houston, TX. Investigation of the outbreak suggested 
transmission through sharing of improperly cleaned blood glucose monitoring devices. In 
August 2010, the Houston Department of Health and Human Services with assistance from 
CDC implemented hepatitis B screening and vaccination of residents in the four facilities to 
prevent further transmission of hepatitis B.
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2.2. Data collection and vaccine administration
Informed consent for hepatitis screening and vaccination was obtained from residents and/or 
their guardians. Those who consented were screened for hepatitis B and C infection and 
those who were found to be susceptible for hepatitis B infection (antibodies to hepatitis B 
surface antigen (anti-HBs) = 0 mIU/mL, negative hepatitis B surface antigen (HBsAg), and 
negative hepatitis B core antibody (anti-HBc)) were vaccinated using a 23-gauge one inch 
needle in the right or left deltoid muscles with one dose of 20 μg Engerix-B™ 
(GlaxoSmithKline Biologicals, lot no.: 11,AHBVB798AA) on a 0, 1, and 4 month schedule. 
Vaccines and serological testing were provided by the Texas Department of Health and 
Human Services and CDC, respectively, as part of the outbreak response.
Information was abstracted from medical records of the residents at the four facilities to 
obtain basic demographic (age, sex, race, and ethnicity) and clinical characteristics which 
might affect vaccine response such as smoking, body mass index (BMI), diabetes status, 
alcohol use, renal disease (ranging from moderate renal disease to renal failure and 
hemodialysis), liver disease (any liver disease including hepatitis C infection, liver failure, 
cirrhosis), cancer (previous or current), HIV status, use of immunosuppressive drugs or 
chemotherapy, and the presence of comorbid conditions. Body mass index was classified 
according to guidelines as underweight (BMI < 18.5), normal (18.5 ≤ BMI < 25 kg/m2), 
overweight (25 ≤ BMI < 30 kg/m2), and obese (BMI ≥ 30 kg/m2) [8].
2.3. Serology testing
Blood samples were collected for serological testing at pre-vaccination (day 0) and 80–90 
days after the third vaccine dose. The level of total antibodies to hepatitis B surface antigen 
(quantitative anti-HBs), and qualitative determination of hepatitis B core antibody (total 
anti-HBc and anti-HBc IgM), hepatitis B surface antigen (HBsAg), and immunoglobulin G 
antibody to hepatitis C virus (IgG anti-HCV) were determined using the VITROS ECi 
Immunodiagnostic System (Ortho-Clinical Diagnostics, Inc., Rochester, NY). Anti-HBs 
concentrations ≥ 10 mIU/mL were considered indicators of seroprotection.
2.4. Statistical analysis
Response to hepatitis B vaccine (anti-HBs concentrations ≥ 10 mIU/mL) was assessed by 
demographic and clinical characteristics. Quantitative anti-HBs levels were calculated as 
geometric mean concentrations (GMCs) with 95% confidence intervals (95%CI). Anti-HBs 
levels were log transformed and anti-HBs values below 1 mIU/mL were assigned a value of 
1 mIU/mL before log transformation. Fisher’s exact test was used to test associations 
between demographic and clinical characteristics with seroprotection and t-tests were used 
to compare anti-HBs GMC between groups. SAS v9.2 was used for statistical analysis and a 
p-value <0.05 was considered statistically significant. Houston Department of Health and 
Human Services and CDC IRB approval were not required as a licensed vaccine was 
administered to adults at risk for HBV infection within the context of an acute outbreak.
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3. Results
Of the 289 ALF residents, 136 (47.1%) consented to be screened for hepatitis B and C 
infection; of these, 120 (88.2%) were found to be susceptible to HBV infection, 2 had anti-
HBs ≥ 10 mIU/mL and were negative for HBsAg and anti-HBc, and 14 (10.3%) were 
infected with hepatitis B of which 8 were acute infections (Fig. 1). Of the 69 residents who 
consented to receive 3 doses of hepatitis B vaccine, 48 (69.6%) residents had post-
vaccination blood specimens collected 80–90 days after the third vaccine dose; of these, 16 
(33.3%) achieved anti-HBs concentration ≥ 10 mIU/mL. Among the 32 residents with anti-
HBs concentration <10 mIU/mL, 8 (25%) had detectable anti-HBs concentration (between 1 
and 9.9 mIU/mL) with 2 residents having borderline anti-HBs concentrations of 9.3 
mIU/mL. The anti-HBs GMC among the 48 residents was 4.8 mIU/mL. The basic 
characteristics of residents who did not complete vaccination or did not have serological 
testing were similar to those who completed vaccination and serological testing.
The mean age of vaccinated residents was 82.2 ± 14.2 years; the median age was 86 years, 
range (45–102 years). Demographic and clinical characteristics are shown in Table 1. The 
residents included more women than men and all residents with available race and ethnicity 
information were non-Hispanic white. Although there were more than 30 residents with 
diabetes living in the four ALFs, only five agreed to be tested and vaccinated. Residents had 
a mean BMI of 25.4 ± 4.6 (range: 18.9–36.8) and almost all were non-smokers. A total of 
6.3% had a previous history of cancer but none were on chemotherapy, and 12.5% had 
moderate renal disease. None of the residents who agreed to get vaccinated had liver 
disease, HIV infection, were on hemodialysis, or on immunosuppressive drugs. Information 
on medication was available for 27 residents; most were on anti-hypertensive, cardiac and 
thyroid medications.
Age was the only significant determinant of seroprotection. GMCs were significantly lower 
among residents aged 70 years or older compared to those who were aged 60 years or 
younger (mean age: 53; age range: 45–60) (p < 0.001) (Table 1). No statistically significant 
difference was found between diabetic and non-diabetic residents who developed anti-HBs 
concentration ≥ 10 mIU/mL even after controlling for age; however, GMC were higher 
among non-diabetic compared to diabetic residents (5.1 vs. 3.8 mIU/mL, p = 0.7). Of the 5 
diabetic residents, only one responded to the vaccine and was relatively younger in age 
compared to those who did not respond (77 years old vs. 80, 84, and 93 (n = 2) years old). In 
addition, residents with higher BMI had higher anti-HBs GMCs but the difference was not 
statistically significant. We could not determine any association between seroprotection or 
anti-HBs GMCs and smoking, alcohol use, cancer, and renal disease among persons who 
had complete information on those variables (Table 1).
4. Discussion
This paper describes the use of hepatitis B vaccine among older adults in several ALFs 
during an outbreak of hepatitis B. Seroprotection (anti-HBs concentration ≥ 10 mIU/mL) 
was achieved by one third of vaccinated respondents with available anti-HBs levels after 
receipt of the third vaccine dose. Very few studies have assessed the response to hepatitis B 
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vaccine among older adults (aged 60 years or older); available data suggest variable 
seroprotection rates, ranging between 30% and 80%, depending on the characteristics of the 
study population, the type of vaccine, and vaccination schedule [9–14]. Using a 0, 1, 6 
month vaccination schedule might have achieved a better booster effect with the third dose 
given at 6 months and residents with anti-HBs concentrations between 1 and 10 mIU/mL 
might have achieved seroprotection if the third dose was given at a later time. However, we 
have used the 0, 1, 4 month vaccination schedule given the urgency to respond to the 
outbreak, and the need to achieve seroprotection as early as possible using an approved 
hepatitis B vaccination schedule for adults [2]. Moreover, using the shortest approved 
schedule was operationally easier to implement in this situation and ensured the ability to 
complete all three doses and cover most residents before their discharge.
Although a small proportion of residents achieved seroprotection, we did not detect 
additional new infections after re-testing for hepatitis B and C markers post-vaccination 
which might be a result of multiple factors. While anti-HBs concentration continues to be 
the standard used to evaluate vaccine-induced immunity, recent studies have shown that 
other components of the immune system, such as cell-mediated immunity, may play a role 
in long-term protection [15]. In addition, the timing of anti-HBs testing influences the 
seroprotection rates [2,9]. Testing for anti-HBs concentration is recommended 30–60 days 
after the third vaccine dose; however, because we tested for anti-HBs concentration 80–90 
days after the last vaccine dose, we could have missed some who initially responded to the 
vaccine. Therefore, the eight residents with anti-HBs levels between one and 10 mIU/mL 
may have had anti-HBs levels ≥ 10 mIU/mL during the 30–60 day period but their antibody 
levels declined thereafter. In addition, improvements in infection control practices as a result 
of the outbreak might have contributed to the prevention of new infections.
Age was the only significant predictor of seroprotection in our study population. Residents 
aged 60 years or younger achieved a high seroprotection rate of 88%; however, rates 
reached 30% and 12% among those aged 80–89 and ≥90 years, respectively. In addition, as 
age increased there was a significant decrease in anti-HBs GMCs. These findings are 
consistent with previously published reports [2,14,16] and are presumably the result of the 
phenomenon of immunosenescence [15,17]. In this older population, higher BMI may have 
been a surrogate marker for better nutritional status, which in turn contributes to a stronger 
immune system, leading to higher seroprotection rates among those who are overweight or 
obese compared to those having normal BMI (27.8% vs. 9.1%). Only five diabetic residents 
had post-vaccine testing results which probably hindered our ability to detect any 
association between diabetes status and vaccine response.
This study had several limitations, including the small sample size, which precluded the 
determination of statistically significant associations between risk factors and 
seroprotection. Moreover, our population consisted of older adults living in ALFs who 
might not be representative of older adults living in the community. In addition, almost one 
third of the study population had missing information in their medical records on co-morbid 
conditions and a reliable verbal history was difficult to obtain given the high prevalence of 
dementia in this population. Similarly, information on receipt of prior hepatitis B 
vaccination was obtained strictly through review of medical records available at ALFs. 
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Some persons with undetectable anti-HBs could have been vaccinated previously. In such 
cases, a response to vaccination would truly have represented a response to revaccination, 
thereby falsely elevating our estimate of primary vaccine response.
Despite these limitations, the findings in this study contribute valuable observational data 
regarding response to hepatitis B vaccination of older adults in LTC settings. Only one third 
of the vaccinated older adults developed seroprotection. From an outbreak control 
standpoint, the combination of poor vaccine response and time interval required to complete 
the vaccine series are likely to limit the usefulness of such an intervention among elderly 
persons. However, recent trends suggest that hepatitis B outbreaks in LTC facilities resulting 
from improper infection control practices are likely to continue [3–6]. Although 
implementation of proper infection control practices is essential in LTC facilities, studies 
have shown the difficulty in sustaining these practices even after an outbreak has occurred in 
these facilities [7]. Until more immunogenic hepatitis B vaccines are available, populations 
deemed presently at risk – or those likely to incur risk in the future – are more likely to 
benefit from vaccination at earlier ages when immune response is more favorable. If 
hepatitis B vaccination of an older population is necessary, an alternative approach such as a 
double dose or extra doses of either single- or combined-antigen hepatitis B vaccine may be 
useful, as has been demonstrated among other immunosuppressed populations at risk for 
HBV infection [2].
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Fig 1. 
Participant flow chart for hepatitis B screening and vaccination—Houston, 2010. ALF: 
assisted living facility; HBV: hepatitis B virus; anti-HBs: antibody to hepatitis B surface 
antigen; anti-HBc: hepatitis B core antibody; HBsAg: hepatitis B surface antigen.
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